Hoth Therapeutics Inc. (HOTH) Begins First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa
- S&P 500, Dow end at record highs as weak jobs data eases rate worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar broadly weaker after U.S. jobs data disappoint
- Square (SQ) Tops Q1 EPS by 25c
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.
"We are excited to have reached this pivotal milestone in our BioLexa development program," stated Robb Knie, CEO of Hoth Therapeutics. "There continues to be an unmet need for improved therapeutics for patients suffering from mild to moderate eczema. The BioLexa clinical trial brings us one step closer to potentially improve the quality of life for those who need this novel therapeutic."
Hoth is conducting the BioLexa clinical trial in Australia. Additional information and updates on the BioLexa clinical trial can be found by visiting www.hoththerapeutics.com and ClinicalTrials.Gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- iStar Financial (STAR) Announces Jeremy Fox-Geen Stepping Down as Chief Financial Officer
- Telus (TU) Reports Q1 EPS of Cdn$0.27 on Revenues of Cdn$4.02B
- Spire (SR) Tops Q2 EPS by 62c, Revenues Beat; Raises FY21 EPS Outlook Above Consensus
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!